Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON, September 05, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET
2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET
A live webcast of the presentation and fireside chat will be available on the investors section of the Company’s website at www.verastem.com. An archived replay of the presentation and fireside chat will be made available on the same website for approximately 90 days following each event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905929024/en/
Contacts
Investors:
Dan Calkins
Investor Relations
+1 781-469-1694
dcalkins@verastem.com
Ryan Porter
+1 212-600-1902
ryan.porter@argotpartners.com
Media:
Lisa Buffington
Corporate Communications
+1 (781) 292-4502
lbuffington@verastem.com
